HER-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification

Journal of Pediatric Hematology/Oncology

Volumn 25, Issue 1, 2003, Pages 27-32

  Zhou, Holly ^a   Randall, R Lor ^a   Brothman, Arthur R ^a   Maxwell, Teresa ^a   Coffin, Cheryl M ^a   Goldsby, Robert E ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

FISH analysis; Her 2 neu staining; Osteosarcoma; Pulmonary metastasis

Indexed keywords

GAMMA UROGASTRONE;

ADOLESCENT; ARTICLE; BONE BIOPSY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG METASTASIS; MALE; ONCOGENE NEU; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; TISSUE FIXATION;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; OSTEOSARCOMA; PILOT PROJECTS; PROGNOSIS; RECEPTOR, ERBB-2; RISK FACTORS; SURVIVAL RATE; UP-REGULATION;

EID: 0037227104     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200301000-00007     Document Type: Article

References (19)

1. Ferguson WS. Goorin AM. Current treatment of osteosarcoma. Cancer Invest 2001;19:292-315.
2. Bacci G, Briccoli A, Mercuri M, et al. Osteosarcoma of the extremities with synchronous lung metastases: long-term results in 44 patients treated with neoadjuvant chemotherapy. J Chemother 1998;10:69-76.
3. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1997;15:76-84.
4. Onda M, Matsuda S, Higaki S, et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 1996;77:71-8.
5. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999;17:2781-8.
6. Morris CD, Gorlick R, Huvos G, et al. Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. Clin Orthop 2001;59-65.
7. Kilpatrick SE, Geisinger KR, King TS, et al. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol 2001;14:1277-83.
8. Akatsuka T, Wada T, Kokai Y, et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 2002;94:1397-404.
9. Maitra A, Wanzer D, Weinberg AG, Ashfaq R. Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. Cancer 2001;92:677-83.
10. van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988;319:1239-45.
11. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986;319:226-30.
12. Akiyama T, Sudo C, Ogawara H, et al. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232:1644-6.
13. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of the Erb/HER signaling network of growth factor receptors. Adv Cancer Res 2000;77:25-79.
14. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994;1198:165-84.
15. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989;244:707-12.
16. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 1994;12:423-31.
17. Wrba F, Gullick WJ, Fertl H, et al. Immunohistochemical detection of the c-erbB-2 proto-oncogene product in normal, benign and malignant cartilage tissues. Histopathology 1989;15:71-6.
18. Brandwein M, Al-Naeif NS, Manwani D, et al. Sialoblastoma: clinico-pathological/immunohistochemical study. Am J Surg Pathol 1999;23:342-8.
19. Osako T, Miyahara M, Uchino S, et al. Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology 1998;55:548-55.